Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

Related Keywords

United States ,Osaka ,Japan ,Japanese ,American ,Bin Chen ,John Cunningham ,Jun Saito ,Cancer Center ,International Blood Marrow Transplant Research ,Hematopoietic Cell Transplant Therapy Program ,Exchange Commission ,European Union ,European Medicines Agency ,Takeda Pharmaceutical Company Limited ,Met Its Primary Efficacy Endpoint ,Clinically Meaningful Intestinal ,Free Survival ,New Safety Signals Were Seen ,Vedolizumab Compared ,Patients Who Received ,Were Presented ,Late Breaking Abstract ,Cellular Therapy Meetings ,American Society ,Cellular Therapy ,International Blood ,Marrow Transplant Research ,Yi Bin Chen ,Hematopoietic Cell Transplant ,Cell Therapy Program ,Mass General Cancer ,Safety Information ,Special Precautions ,Site Reactions ,Product Characteristics ,Prescribing Information ,Medication Guide ,Rare Genetics ,Plasma Derived Therapies ,Annual Report ,Lower Gastrointestinal ,Acute Graft Versus Host Disease ,From Unrelated Donors ,Multicenter Study ,From Pharmacological Prophylaxis ,Intestinal Acute Graft Versus Host Disease ,Annexi Summary ,For Medicinal Products Human ,Pharmacol Exp ,Vedolizumab Patient Exposure ,Media Contact ,Takeda Pharmaceutical ,Hase 3 Study Of Vedolizumab ,Graft Versus Host ,Revention Of Intestinal Acute ,Agvhd ,Allogeneic Hematopoietic Stem Cell Transplantation ,Allo Hsct ,Hase 3 Graphite Study ,Eaningful Intestinal Agvhd Free ,A Late Breaking Abstract ,Llo Hsct Data ,American Society For Transplantation And Cellular Therapy ,Astct ,Enter For International Blood Marrow Transplant Research ,Cibmtr ,